News

News

Momelotinib Trial in Myelofibrosis Fails to Meet Primary Endpoint

The Janus kinase (JAK) inhibitor ruxolitinib is the only treatment approved by the U.S. Food and Drug Administration for patients with myelofibrosis (MF), and...

Can R-CHOP Plus Bortezomib Improve Outcomes in Patients With Non-GCB DLBCL?

In patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), adding the proteasome inhibitor bortezomib to standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) did...

Adding Pharmacomechanical Thrombolysis to Anticoagulation Does Not Improve Outcomes in Proximal DVT

The objective of pharmacomechanical thrombolysis, or the delivery of a fibrinolytic drug into the thrombus with concomitant thrombus aspiration, is to diminish the thrombus...

Is Oral Edoxaban an Alternative to Standard Anticoagulation in Cancer-Associated VTE?

Low-molecular-weight heparin is the standard, guideline-recommended anticoagulation therapy for patients with cancer and venous thromboembolism (VTE), but the daily subcutaneous injections can be burdensome....

Understanding Bone Disease and Fractures in Patients With MGUS

Patients with monoclonal gammopathy of undetermined significance (MGUS; a precursor to multiple myeloma and other lymphoproliferative disorders) are known to be at an...
WIB_icon

Can AMT-060 Gene Therapy FIX Hemophilia B?

After a single infusion of AMT-060 (an adeno-associated virus-5 vector carrying a corrected human factor IX gene), patients with hemophilia B experienced...
WIB_icon

Early-Phase Study Finds Duvelisib Active in Variety of Advanced Hematologic Malignancies

The oral phosphoinositide 3-kinase (PI3K) dual inhibitor duvelisib appeared to be active and tolerable at a range of doses and across a variety of...
WIB_icon

Brentuximab Vedotin Plus Nivolumab May Be an Alternative to Salvage Chemotherapy in Relapsed/Refractory Hodgkin...

In a phase I/II study published in Blood, the combination of brentuximab vedotin plus nivolumab was an effective first salvage therapy in patients with...
WIB_icon

Single-Agent Vadastuximab Talirine Active, Tolerable in AML

In a first-in-human study of patients with CD33-positive acute myeloid leukemia (AML), treatment with single-agent vadastuximab talirine (a CD33-targeted antibody-drug conjugate) resulted in a...

FDA Delays BLA Review for Andexanet Alfa as Anticoagulation Reversal Agent

The FDA extended by 90 days its review of the biologics license application (BLA) for andexanet alfa for the second time, from February 3...
Advertisement

Current Issue

February 2018 Volume 4, Issue 3

This issue features a conversation with National Cancer Institute Director Norman “Ned” Sharpless, MD, a look at the prevalence and controversial nature of academic-industry partnerships, and more.